← 홈

Catalyst · Landscape

향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS

파이프라인 Phase 분포

큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.

Preclinical
132
Phase 1
491
Phase 2
979
Phase 3
293
Approved
134

Catalyst target · modality

향후 6개월 catalyst 3건 · 타깃·모달리티 분포

Antibody 3
Colorectal
2
HER2
1

향후 6개월 Catalyst(3 / 80)

활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시

완료 예정프로그램PhaseStatusEndpoint신뢰도NCT
2026년 9월ErbituxAntibody · Colorectal CancerPhase 3Active, not recruitingOverall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set신뢰 높음NCT04590963
2026년 9월IvonescimabAntibody · HER2Phase 2Not yet recruiting6-month-PFS rate보통NCT06991491
2026년 9월ErbituxAntibody · Colorectal CancerPhase 1, Phase 2Active, not recruitingDose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.; Dose escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment; Dose escalation: Frequency of dose interruptions and reductions, by treatment; Dose Escalation: Dose intensity by treatment; PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1신뢰 높음NCT05358249
  • 2026년 9월신뢰 높음
    Erbitux

    Antibody · Colorectal Cancer · Phase 3

    Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set

    NCT04590963
  • 2026년 9월보통
    Ivonescimab

    Antibody · HER2 · Phase 2

    6-month-PFS rate

    NCT06991491
  • 2026년 9월신뢰 높음
    Erbitux

    Antibody · Colorectal Cancer · Phase 1, Phase 2

    Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.; Dose escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment; Dose escalation: Frequency of dose interruptions and reductions, by treatment; Dose Escalation: Dose intensity by treatment; PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1

    NCT05358249